New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export PBM’s income statement to Excel — free account
Psyence Biomedical Ltd.
PBM
2.97
0.11
+3.85%
After hours trading: 3.01, up 1.35%, last trade Fri 4:09pm Eastern.
Follow PBM
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | 8 | 8 | (51) | (51) | 1 | (7) | n/m | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Net income | 0 | — | — | — | 8 | 8 | 0 | (51) | 1 | (7) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | — | |||||
| Earnings | — | — | — | — | 0.25 | 0.25 | (6.14) | (29,211.54) | 32.75 | (12.56) | n/m | ||||||
| Cash flow | — | — | — | — | (0.03) | (0.02) | — | (1,732.59) | (120.85) | (14.74) | n/m | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | — | (3.35) | (0.32) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | (0.03) | (0.02) | — | (1,735.94) | (121.17) | (14.74) | n/m | ||||||
| Book value | — | — | — | — | 7.24 | 7.49 | (1.32) | (6,454.41) | 217.54 | 30.68 | +33.5% | ||||||
| Shares, m | — | — | — | — | 33 | 33 | 8 | 0 | 0 | 1 | (55.8%) | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (1) | (1) | — | (3) | (4) | (8) | n/m | |||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | (81.3%) | ||||||
| Free cash flow | — | — | — | — | (1) | (1) | — | (3) | (4) | (8) | n/m | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 1 | (13) | (11) | (11) | 6 | 8 | +56.5% | |||||
| Net debt | — | — | — | — | (1) | 0 | (1) | (1) | (6) | (7) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | 237 | 245 | (11) | (11) | 7 | 17 | (41.0%) | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | 6.42 | 3.11 | (39.34) | (4,518.56) | 23.95 | (55.75) | (62.2) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | (415.57) | (41.24) | (41.2) pt | ||||||
| ROE | — | — | — | — | — | 3.33 | (54.66) | 149.52 | (47.61) | (58.62) | (61.9) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 10 | 12 | 12 | +9.5% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | — | ||||||
Negative figures in brackets.
estimates
Psyence Biomedical Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics, Inc. | $11.9M | — (loss-making) | — | — | n/m | +67.81% (above 0%: growing) | 0.09% | (1,802.16%) | Compare |
| BCDA BioCardia, Inc. | $11.7M | — (loss-making) | — (loss-making) | −93.02% (below 0%: shrinking) | n/m | −2.93% (below 0%: shrinking) | 100.00% | (54,966.67%) | Compare |
| PASG Passage Bio, Inc. | $11.6M | — (loss-making) | — | — | n/m | +17.68% (above 0%: growing) | 0.00% | — | Compare |
| AEON AEON Biopharma, Inc. | $11.2M | — (loss-making) | — | — | n/m | −120.53% (below 0%: shrinking) | — | — | Compare |
| PBM Psyence Biomedical Ltd. | $10.9M | 0.1× | — | — | n/m | −1,628.07% (below 0%: shrinking) | — | — | |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | $10.6M | — | — | — | — | — | — | — | Compare |
| HIND Vyome Holdings, Inc. | $10.2M | — (loss-making) | — (loss-making) | +67.63% (above 0%: growing) | n/m | +63.50% (above 0%: growing) | 46.21% | (1,760.52%) | Compare |
| LSTA Lisata Therapeutics, Inc. | $9.8M | — (loss-making) | — (loss-making) | — | n/m | −279.44% (below 0%: shrinking) | 100.00% | (3,080.00%) | Compare |
| BIVI BioVie Inc. | $9.8M | — (loss-making) | — | — | n/m | +3.92% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $10.9M | — | — | — | — | +3.92% | 23.15% | (1,802.16%) |
Psyence Biomedical Ltd. (PBM) Latest News
- Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met GlobeNewswire
- Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine GlobeNewswire
- Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation GlobeNewswire
- Psyence BioMed Announces Strategic Ibogaine Investment
- Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
- Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
- Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing GlobeNewswire
- FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain MT Newswires
- Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
- Trump Trade: President to sign order on psychedelic used for PTSD TipRanks
20 more headlines
- Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder GlobeNewswire
- Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness
- Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine GlobeNewswire
- Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities GlobeNewswire
- Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone GlobeNewswire
- Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results TipRanks
- Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial GlobeNewswire
- Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment GlobeNewswire
- Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway GlobeNewswire
- Psyence BioMed Announces Settlement of Shareholder Litigation GlobeNewswire
- Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split GlobeNewswire
- Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split GlobeNewswire
- Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity GlobeNewswire
- Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash GlobeNewswire
- Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial GlobeNewswire
- Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science GlobeNewswire
- Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program GlobeNewswire
- Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets GlobeNewswire
- Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs GlobeNewswire
- Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care GlobeNewswire